PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
Open Access
- 15 October 2019
- journal article
- research article
- Published by Springer Nature in EJNMMI Research
- Vol. 9 (1) , 1-13
Abstract
Background: Prostate-specific membrane antigen (PSMA) is overexpressed on the endothelial cells of tumor neo-vessels of several solid malignancies, including differentiated thyroid cancer (DTC). We aimed to test the potential role of PSMA as a biomarker for DTC aggressiveness and outcome prediction. We retrospectively screened all patients who underwent thyroidectomy between 1 January 2010 and 31 December 2017 in our institution. Applying the inclusion (histological diagnosis of thyroid cancer and tissue availability) and exclusion criteria (no clinical or follow-up data or diagnosis of medullary thyroid cancer), a cohort of 59 patients was selected. The monoclonal mouse anti-human PSMA antibody was used to stain tissue sections. A 3-point scale was used to score PSMA positivity: 0–5% expression was considered as negative (score 0), 6–50% as moderately positive (score 1), and 51–100% as highly positive (score 2). A cumulative score (0–10%, 11–79%, and 80–100%) was also explored. Univariate and multivariate logistic regression analyses were performed to predict the presence of distant metastases, chosen as endpoint of aggressiveness. The area under the curve (AUC) was calculated. Cox models were built to predict patient outcome in terms of recurrence, iodine refractoriness, and status at last follow-up, which were calculated using the Kaplan-Meier failure function. Results: At immunostaining, 12, 25, and 22 patients had scores of 0, 1, and 2, respectively. According to the cumulative score, PSMA expression was ≤ 10% in 17 cases, 11–79% in 31 cases, and ≥ 80% in 11 cases. At multivariate analysis, age, sex, histotype, vascular invasion, T and N parameters, and PSMA positivity were significant predictors of distant metastases. The AUC was 0.92. Recurrence or progression occurred in 19/59 patients. Twelve patients developed radioiodine (RAI) refractoriness, after a median time of 17 months (range 2–32). One patient died of DTC; 46 of the 58 patients alive at last follow-up were disease free. Median DFS was 23 months (range 3–82). The final multivariate model to predict RAI refractoriness included as covariates the stage, high PSMA expression (≥ 80%), and the interaction between moderate PSMA expression (11–79%) and stage. Conclusions: PSMA, a marker of neovasculature formation expressed by DTC, contributes in the prediction of tumor aggressiveness and patient outcome.Keywords
This publication has 38 references indexed in Scilit:
- Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CTClinical Nuclear Medicine, 2016
- PSMA Expression in Papillary Thyroid CarcinomaClinical Nuclear Medicine, 2016
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expressionLaboratory Investigation, 2010
- Association of BRAFV600EMutation with Poor Clinical Prognostic Factors and US Features in Korean Patients with Papillary Thyroid MicrocarcinomaRadiology, 2009
- Molecular markers of aggressiveness of thyroid cancerCurrent Opinion in Endocrinology, Diabetes and Obesity, 2009
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyThe Journal of Clinical Endocrinology & Metabolism, 2006
- Distant Metastases from Thyroid and Parathyroid CancerORL, 2001
- Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluidsInternational Journal of Cancer, 1995